Indication intelligence, analysis and sector perception

Caladrius Biosciences (CLBS) Out-licenses CD34 technology

January 11, 2016 10:57am

SPS Cardio, LLC licenses Chronic Heart Failure (CHF) Acute Myocardial Infarction (AMI) program for development in India and certain “territories” – Dead money at $0.53 - HOLD

Empties the cupboard but no bucks or bang, all in the form of royalties and “potential “payments to the future (which century) after all the money spent - $40 M +

CLBS has entered into an agreement with SPS Cardio, LLC to exclusively out-license the commercialization rights to its CD34 ischemic repair technology (CLBS10) for the indications of acute myocardial infarction (AMI) and chronic heart failure (CHF) in select territories outside of the U.S.

SPS is a venture capital firm (?) that will fund this technology’s further development in these indications and designated countries. SPS intends to conduct a P2 proof-of-concept clinical trial in India.

The Bottom Line: CLBS will be eligible to receive royalties together with a milestone upon the successful development and commercialization of any product … eventually sold in the selected territories.

Who are the BOD and executives that acquired and championed the technology to NBS <now CLBS> and then modified the end-points? That story needs to be told …

CLBS retains the rights to unfettered, cost-free access to and use of any and all clinical and non-clinical data generated in India – why, the piggy-back, there isn’t any money in the till to further develop anywhere else?

CLBS is trading FLAT at $0.53 far from the $3.77 when CEO Mazzo was “anointed”.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

5 hours 29 min ago
RegMed Investors’ (RMi) pre-open: It’s “make” a buck day!

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.